RxDoctor Payments Data

Charles Kaplan, MD

Internal Medicine · Tucson, AZNPI 1538117536

Payments from drug & device makers

$430in general payments, 2019–2025

Across 21 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$64
  • Ferring Pharmaceuticals Inc.$47
  • Sumitomo Pharma America, Inc.$44
  • Abbott$39
  • GSK$36
  • Pfizer$31
  • plus $168 from 8 others

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$430 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$178,146
Medicare patients
390
Services billed
6,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$112,267
JardianceEmpagliflozin86$109,313
TrulicityDulaglutide48$79,695
ProliaDenosumab28$49,417
MounjaroTirzepatide31$46,330
JanuviaSitagliptin Phosphate40$43,124
XareltoRivaroxaban28$42,337
RybelsusSemaglutide19$34,673
MyrbetriqMirabegron25$24,354
OzempicSemaglutide23$21,429
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$20,312
VimpatLacosamide12$20,005
Repatha SureclickEvolocumab21$15,095
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,719
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$12,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$112,267101 claims
AmgenProlia$31$49,41728 claims
Johnson & JohnsonXarelto$21$42,33728 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$36$30,97349 claims
Sumitomo Pharma America, Inc.Gemtesa$44$4,82211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →